Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00657137
What this trial is testing

APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)

Who this might be right for
Breast Cancer
Tragara Pharmaceuticals, Inc. 12
Testing effectiveness (Phase 2)UnknownNCT03997539
What this trial is testing

Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-sen University 256
Large-scale testing (Phase 3)Active Not RecruitingNCT03529110
What this trial is testing

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Who this might be right for
Breast Cancer
Daiichi Sankyo 524
Testing effectiveness (Phase 2)Study completedNCT01044485
What this trial is testing

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Centre Georges Francois Leclerc 17
Large-scale testing (Phase 3)Study completedNCT01120184
What this trial is testing

Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,095
Testing effectiveness (Phase 2)WithdrawnNCT05227131
What this trial is testing

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerHER2-positive Breast Cancer
MedSIR
Early research (Phase 1)Active Not RecruitingNCT04042701
What this trial is testing

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Who this might be right for
Breast CancerNon-small Cell Lung Carcinoma
Daiichi Sankyo 115
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07786051
What this trial is testing

DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 80
Testing effectiveness (Phase 2)Looking for participantsNCT06176261
What this trial is testing

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Who this might be right for
Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more
Nancy Lin, MD 58
Early research (Phase 1)Not Yet RecruitingNCT07454668
What this trial is testing

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Who this might be right for
Breast CancerHER2-positive Breast CancerBrain Metastases+2 more
Baptist Health South Florida 20
Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Testing effectiveness (Phase 2)UnknownNCT01283789
What this trial is testing

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 23
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556
What this trial is testing

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd. 96
Large-scale testing (Phase 3)Study completedNCT01007942
What this trial is testing

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2/Neu Over-expressing Locally Advanced Breast CancerMetastatic Breast Cancer
Novartis Pharmaceuticals 569
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Early research (Phase 1)Study completedNCT02900664
What this trial is testing

PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Who this might be right for
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis Pharmaceuticals 283
Not applicableStudy completedNCT06344793
What this trial is testing

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 608
Next Page